119-HR-6580 Journalist Public Summary

Headline Summary

Make the VA’s national drug list uniform, faster, and more transparent—while letting VA cut better deals on medicine prices and set lower copays for generics and on‑formulary drugs.

What It Does

The bill writes the Department of Veterans Affairs’ National Formulary into law and standardizes how it’s run. The VA already maintains a nationwide drug list; this proposal would codify it, publish reasons for big changes, and set clear timelines and appeals so veterans and clinicians get quicker, more consistent decisions. (pbm.va.gov)

• Uniform, one national list across all VA facilities, with limited waivers for defined programs or patient groups.
• Faster reviews for new FDA‑approved drugs, aiming for a decision within 120 days.
• A transparent Pharmacy & Therapeutics Committee (physicians, clinical pharmacists, pharmacoeconomists) with conflict‑of‑interest safeguards and public summaries of major add/remove decisions.
• A standard electronic non‑formulary request and appeal path: initial decision within 96 hours; appeal resolved within 7 days; approvals travel with the patient across VA sites.
• Regular class reviews and medication‑therapy management to reduce risky polypharmacy.
• Public reporting to Congress and online summaries of significant formulary changes.
• Price and value tools: VA may negotiate supplemental discounts and value‑based deals tied to outcomes, while keeping existing federal price caps intact.
• Copays: creates a tier so generics/on‑formulary drugs cost less than brand‑name or non‑formulary drugs.

Who’s For It

• Sponsor: Rep. Mariannette Miller‑Meeks (R‑IA), who introduced the bill on December 10, 2025. (congress.gov)
• House Veterans’ Affairs Committee Republican leaders have promoted a package to modernize VA healthcare, including making the national drug formulary more transparent and consistent—signaling likely support for reforms in this space. (veterans.house.gov)
• As of March 19, 2026, Congress.gov lists no cosponsors. (congress.gov)

Who’s Against It

• No high‑profile, on‑the‑record opposition is readily visible yet in official listings; debate will likely focus on trade‑offs rather than outright support or opposition.
• Potential concerns some clinicians or advocates could raise: centralized formulary rules might constrain bedside discretion; value‑based or preferred‑status deals could steer prescribing; and higher copays for brand/non‑formulary drugs might burden patients who truly need them.
• Supporters would counter that the bill preserves case‑by‑case access through a faster non‑formulary process and waivers, while adding transparency and leveraging VA’s buying power to stretch dollars for veteran care.

What’s Next

As of March 19, 2026, the bill is at the “Introduced” stage—referred to the House Committee on Veterans’ Affairs. Next steps could include subcommittee/committee hearings, a markup, and a committee vote to send it to the full House; if it passes, it would move to the Senate. (congress.gov)